POWERFUL NEWS:

MMRF PRESS RELEASES


Multiple Myeloma Research Consortium (MMRC) Unveils 16 Abstracts at Ash


Abstracts include updated data from clinical trials and new findings from the MMRF Genomics Initiative

Norwalk, CT — November 23, 2009

The Multiple Myeloma Research Consortium (MMRC) announced today that data from 13 of its clinical trials and three from the Multiple Myeloma Research Foundation (MMRF) Genomics Initiative, which analyzes tissue samples from the MMRC tissue bank, have been selected for oral or poster presentations at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH) to be held in New Orleans from December 5-8, 2009.
“It is truly exciting to see how quickly the promise of the MMRC has come to fruition,” stated Kathy Giusti, founder and CEO of both the MMRF and the MMRC and a multiple myeloma patient. "To be a part of 16 abstracts shows us that the MMRC—which only began five years ago—has proven its ability to choose promising compounds from the beginning. While our Genomics Initiative is helping to build a model for personalized medicine, the MMRC continues to deliver on our commitment to bring the next generation of therapies to patients as quickly as possible. "

Details on the Abstracts selected for both oral and poster presentations are as follows:

ORAL

Abstract #: 132
TITLE: Lenalidomide, Bortezomib, Peglylated Liposomal Doxorubicin and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I / II
MMRC Trial Lead Author: Andrzej Jakubowiak, MD, PhD
Date: Sunday, December 6, 2009
Presentation Time: 5:45 PM
Location: Ernst M. Memorial Convention Center, Hall F

Abstract #: 748
TITLE: Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
Lead Author: Irene Ghobrial, MD
Date: Monday, December 7, 2009
Presentation Time: 5:15 PM
Location: Ernst M. Memorial Convention Center, Hall F

Abstract #: 430
TITLE: Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, is Associated with Minimal Peripheral Neuropathic Effects
Lead Author: Ravi Vij, MD
Date: Monday, December 7, 2009
Presentation Time: 11:15 AM
Location: Ernst M. Memorial Convention Center, Hall F

Abstract #: 432
TITLE: Phase I / 2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results
MMRC Trial Lead Author: Sagar Lonial, MD
Date: Monday, December 7, 2009
Presentation Time: 11:45 AM
Location: Ernst M. Memorial Convention Center, Hall F

Abstract #: 431
TITLE: Phase I Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Lead Author: Paul Richardson, MD
Date: Monday, December 7, 2009
Presentation Time: 11:30 AM
Location: Ernst M. Memorial Convention Center, Hall E

Abstract #: 303
TITLE: PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Multiple Myeloma (MM); Updated Results from the Bortezomib-Treated Cohort
Lead Author: David Siegel, MD, PhD
Date: Monday, December 7, 2009
Presentation Time: 7:30 PM
Location: Ernst M. Memorial Convention Center, Hall F

Abstract #: 302
TITLE: Updated Results of Bortezomib-Naïve Patients in PX-171-004, an Ongoing Open-Label Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Multiple Myeloma (MM)
Lead Author: Luhua Vang, MD
Date: Monday, December 7, 2009
Presentation Time: 7:15 PM
Location: Ernst M. Memorial Convention Center, Hall F

Abstract #: 301
TITLE: A Phase I /2 Multi-Center, Randomized, Open-Label, Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma who Have Received Prior Treatment that Includes Lenalidomide and Bortezomib
Lead Author: Paul Richardson, MD
Date: Monday, December 7, 2009
Presentation Time: 7:00 PM
Location: Ernst M. Memorial Convention Center, Hall AB

Abstract #: 832
TITLE: HOXA9 is a Novel Therapeutic Target in Multiple Myeloma
Lead Author: Michael Chapman, M.A.
Date: Monday, December 7
Presentation Time: 6:45 PM
Location: Ernst M. Memorial Convention Center, Room 293-296

Abstract #: 601
TITLE: Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target that Regulates STAT3/MCL1
Lead Author: Roger Tiedmann, MBChB, PhD
Date: Monday, December 7, 2009
Presentation Time: 2:45 PM
Location: Ernst M. Memorial Convention Center, La Nouvelle Ballroom C

Abstract #: 604
TITLE: CpG Methylation Profiling in Multiple Myeloma
MMRC Trial Lead Author: Bodour Salhia, PhD
Date: Monday, December 7, 2009
Presentation Time: 3:30 PM
Location: Ernst M. Memorial Convention Center, Ballroom C

POSTERS

Abstract #: 1877
TITLE: A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.
Lead Author: Ruben Niesvizky, MD
Date: Saturday, December 5, 2009
Presentation Time: 5:30 PM- 7:30 PM
Location: Ernst M. Memorial Convention Center, Hall E
Poster Board no: I-899

Abstract #: 3851
TITLE: A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
Lead Author: Sagar Lonial, MD
Date: Monday, December 7, 2009
Presentation Time: 6:00 PM
Location: Ernst M. Memorial Convention Center, Hall E
Poster Board no: III-787

Abstract #: 3879
TITLE: Preliminary Results of A Phase I Study of the Pan-P13 Kinase Inhibitor SF1126 in Patients with Relapsed/Refractory Multiple Myeloma
Lead Author: Sagar Lonial, MD
Date: Monday, December 7, 2009
Presentation Time: 6:00 PM
Location: Ernst M. Memorial Convention Center, Hall E
Poster Board no: III-815

Abstract #: 3876
TITLE: Phase 1 / 2 Study of Elotuzomab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results
Lead Author: Andrzej Jakubowiak, MD, PhD
Date: Monday, December 7, 2009
Presentation Time: 7:15 PM
Location: Ernst M. Memorial Convention Center, Hall E
Poster Board no: III-812

Abstract #: 3852
TITLE: A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma
Lead Author: Jesus F. San-Miguel, MD, PhD
Date: Monday, December 7, 2009
Presentation Time: 6:00 PM
Location: Ernst M. Memorial Convention Center, Hall E
Poster Board no: III-788

The abstracts became available for viewing last week on the American Society of Hematology website (www.hematology.org).

About the Multiple Myeloma Research Consortium (MMRC)
The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 14 member institutions: City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, and Washington University.

The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in the today's most promising research areas–genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit: www.themmrc.org.

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised more than $130 million since its inception to fund more than 120 laboratories worldwide. An outstanding 93 percent of funds raised go toward research and related programming. The MMRF has supported 40 new compounds and approaches in clinical trials and pre- clinical studies and has facilitated 21 clinical trials through its sister organization, the Multiple Myeloma Research Consortium (MMRC). For more information about the MMRF, visit www.www.themmrf.org.

Media Contact: Terri Clevenger, 203-227-0209, tclevenger@continuumhealthcom.com